UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

REGENERON PHARMACEUTICALS, INC., Petitioner

v.

NOVARTIS PHARMA AG, NOVARTIS TECHNOLOGY LLC, NOVARTIS PHARMACEUTICALS CORPORATION,

Patent Owner

Case IPR2021-00816

Patent 9,220,631

DECLARATION OF JUERGEN SIGG, PH.D., IN SUPPORT OF NOVARTIS'S
PATENT OWNER RESPONSE



TABLE OF CONTENTS

I.	INTRODUCTION	2
II.	GENENTECH TRIED TO DEVELOP A TERMINALLY STERILIZED PFS FOR INTRAVITREAL INJECTION OF A VEGF ANTAGONIST BUT FAILED	2
III.	SILICONE OIL LEVELS IN COMMERCIALLY AVAILABLE SYRINGES	7
IV.	VETTER'S SKEPTICISM THAT A PFS COULD FUNCTION PROPERLY WITH LESS THAN 100 μG OF SILICONE OIL	9
V.	NOVARTIS WAS NOT ABLE TO TERMINALLY STERILIZE THE LUCENTIS PFS WITH THE PROCESS DESCRIBED IN WO '877	11
VI.	NOVARTIS REDESIGNED IMPORTANT ASPECTS OF THE SYRINGE AFTER FILING WO '877 BUT BEFORE COMPLETING DEVELOPMENT OF THE LUCENTIS PFS	14
VII.	TESTING OF LUCENTIS PFS	16
VIII.	GENENTECH LICENSE	18
IX	DECLARATION	20



I, Juergen Sigg, declare and state as follows:

I. <u>INTRODUCTION</u>


- 1. I am an Executive Director of Science and Technology in Biologics
 Drug Product Development at Novartis Pharma AG ("Novartis"). As part of my
 duties at Novartis, I serve as the lead scientist for formulation and process
 development of assigned biologic drug products.
- 2. I have a degree in pharmaceutical science and a Ph.D. in pharmaceutical technology. Over the course of my career at Novartis, I have been the lead formulation and process development scientist on several prefilled syringe ("PFS") products. My work in this area began in 1995, and continues to this day. Several of the PFS products I worked on, including Xolair® and Extavia®, made it to the market. Relevant here, I served as the technical lead in the development of the Lucentis® PFS.
- 3. I am a named inventor on several patents and patent applications, including U.S. Patent No. 9,220,631 ("'631 patent") and the abandoned patent application WO 2011/006877 ("WO '877").
 - 4. I have personal knowledge of the facts set forth below.

II. GENENTECH TRIED TO DEVELOP A TERMINALLY STERILIZED PFS FOR INTRAVITREAL INJECTION OF A VEGF ANTAGONIST BUT FAILED

5. Lucentis is the brand name for a compound discovered by Genentech called ranibizumab. Ranibizumab functions as a VEGF antagonist and is used to



treat degenerative eye diseases. Lucentis is administered through intravitreal injection into the eye.





10.	
11.	
12.	



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

